What is the expected timeline and key milestones for the review process and related disclosures?
Expected timeline & disclosure milestones
Vyomeâs board has formally launched a âfull review of strategic alternativesâ for Livechain (OTCâŻLICH). In practice, a review of this scope follows a fairly predictable schedule for U.S.âlisted and OTCâtraded companies:
| Milestone | Approx. Timing |
|---|---|
| FormâŻ8âK filing (initial disclosure of the review) â required within 4âŻbusiness days of the board decision. | DayâŻ0â4 |
| Appointment of advisors (investment bankers, legal counsel, valuation experts) â typically announced in a followâup 8âK or press release. | WeekâŻ1â2 |
| Preâliminary materialâchange report (valuation range, potential deal structures, any confidentialityâonly negotiations) â SECârequired âmaterial eventâ update. | WeekâŻ3â4 |
| Shareholder information package / proxy statement â if a transaction or spinâoff is likely, the company must prepare a definitive proxy for a special meeting. | DayâŻ30â45 |
| Special shareholder meeting (or vote on a definitive transaction) â the final decision point on any merger, sale, or restructuring. | ~DayâŻ60â90 |
| Postâreview press release (outcome of the review â sale, spinâoff, or continuation of statusâquo) â often coincides with the meeting or follows it by a few days. | DayâŻ60â95 |
Trading implications
- Volatility window: The first 4â6âŻweeks will see the most price movement as the market digests the initial 8âK, the appointment of advisors, and any early valuation hints. Expect a 10â15âŻ% swing in LICHâs price if the review hints at a premium sale or a restructuring that could unlock value.
- Liquidity considerations: As an OTCâquoted security, LICH already trades on thin volume. Any materialâchange filing typically triggers a shortâterm surge in volume, so be prepared for tight spreads and possible price spikes around each disclosure date.
- Actionable signal: If the 8âK or subsequent updates reveal a valuation range that exceeds the current market price by >20âŻ%, a buyâonâbreakout strategy could be justified. Conversely, if the review suggests a sale at a discount or a spinâoff with limited upside, consider shortâpositioning or hedging with a largerâcap healthcare index.
In short, the next 30â45âŻdays will be the critical window for information flow. Monitor the SECâs EDGAR system for the 8âK and any subsequent materialâchange filings, and be ready to act on the valuation clues that emerge before the ~90âday shareholder decision point.